Nadia Harbeck, MD, PhD, Ludwig Maximilian University of Munich, Munich, Germany, discusses the ongoing ELEANOR study, a multi-national, prospective, non-interventional study (NIS) in patients with HER2-positive early breast cancer observcing real-life extended adjuvant treatment with neratinib and concurrent use of the eHealth solution CANKADO. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.